Scholarlink

Background <p>Necroptosis plays a significant role in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). Nonetheless, the therapeutic potential of necroptosis inhibition in these conditions remains unclear.</p> Methods <p>This study examines the systemic therapeutic effects of Necrostatin-1 (Nec-1), an inhibitor of receptor-interacting serine/threonine kinase 1 (RIPK1), in MRL/lpr lupus-prone mice.</p> Results <p>Immunohistochemical analysis in renal tissue of active LN patients and MRL/lpr mice demonstrated elevated levels of pRIPK1 and pMLKL. A 28-day treatment with Nec-1 significantly ameliorated the histological manifestations of SLE, including alopecia, skin erythema, arthritis, and nephritis, in MRL/lpr mice. Notably, it mitigated acute lesion features such as LN perivascular inflammation and reduced the presence of pRIPK1 and pMLKL positive immune cells in the kidney. Mechanistically, Nec-1 treatment may exert its therapeutic effects on SLE by decreasing the proportion of Th17 cells in MRL/lpr mice.</p> Conclusion <p>These findings suggest that targeting RIPK1 hold promise as a therapeutic strategy for the management of SLE.<Table Float="No" ID="Taba"> <tgroup cols="1"> <colspec align="left" colname="c1" colnum="1" /> <tbody> <row> <entry align="left" colname="c1"> <p><b>Key Points</b></p> </entry> </row> <row> <entry align="left" colname="c1"> <p>• <i>Necroptosis markers are upregulated in renal immune cells of active LN patients and MRL/lpr mice.</i></p> <p>• <i>Necrostatin-1 (Nec-1) ameliorates clinical, serological, and histological features in MRL/lpr mice.</i></p> <p>•<i> Nec-1 exerts its therapeutic effect by inhibiting necroptosis in immune cells, which subsequently reduces Th17 cell frequency and IL-17A levels.</i></p> </entry> </row> </tbody> </tgroup> </Table></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Targeting RIPK1 is a promising therapeutic avenue for systemic lupus erythematosus

  • 期刊论文

  • 发表日期：

    2026年6月19日

查看全文
  • Ming Chen,
  • Liyan Wan,
  • Minhui Wang,
  • Junyu Liang,
  • Yini Ke,
  • Mengdi Jiang,
  • Jing Liu,
  • Heng Cao

摘要

Background

Necroptosis plays a significant role in the pathogenesis of systemic lupus erythematosus (SLE) and lupus nephritis (LN). Nonetheless, the therapeutic potential of necroptosis inhibition in these conditions remains unclear.

Methods

This study examines the systemic therapeutic effects of Necrostatin-1 (Nec-1), an inhibitor of receptor-interacting serine/threonine kinase 1 (RIPK1), in MRL/lpr lupus-prone mice.

Results

Immunohistochemical analysis in renal tissue of active LN patients and MRL/lpr mice demonstrated elevated levels of pRIPK1 and pMLKL. A 28-day treatment with Nec-1 significantly ameliorated the histological manifestations of SLE, including alopecia, skin erythema, arthritis, and nephritis, in MRL/lpr mice. Notably, it mitigated acute lesion features such as LN perivascular inflammation and reduced the presence of pRIPK1 and pMLKL positive immune cells in the kidney. Mechanistically, Nec-1 treatment may exert its therapeutic effects on SLE by decreasing the proportion of Th17 cells in MRL/lpr mice.

Conclusion

These findings suggest that targeting RIPK1 hold promise as a therapeutic strategy for the management of SLE.

Key Points

• Necroptosis markers are upregulated in renal immune cells of active LN patients and MRL/lpr mice.

• Necrostatin-1 (Nec-1) ameliorates clinical, serological, and histological features in MRL/lpr mice.

• Nec-1 exerts its therapeutic effect by inhibiting necroptosis in immune cells, which subsequently reduces Th17 cell frequency and IL-17A levels.